November 20, 2014

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 18, 2014

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer

April 29, 2014

Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Induces Alterations in Gene Expression and Demonstrates Potential Anticancer Activity in Non-Small Cell Lung Cancers, Malignant Pleural Mesothelioma and Melanomas, Cancers That Are Deficient in Key Metabolic Protein

April 02, 2014

Shaw T. Chen, M.D., Ph.D. Joins Polaris as Executive VP of Regulatory Affairs

January 27, 2014

Polaris Group's ADI-PEG 20 is a Radiosensitizer of Pancreatic Cancer


December 02, 2013

Polaris Group Files New IND for ADI-PEG 20 in Leukemia

November 06, 2013

Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

October 28, 2013

Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma

October 22, 2013

Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer

April 17, 2013

Metabolic Changes Induced by Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Are Associated with Anticancer Activity in Bladder Cancer and Mesothelioma Models Especially Those That Are Deficient in Key Metabolic Protein


June 12, 2012

Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma

February 28, 2012

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

January 09, 2012

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer


July 28, 2011

Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma

May 18, 2011

Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20

May 12, 2011

Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan

April 11, 2011

Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically with Inhibitors of Autophagy

April 07, 2011

Transcriptional Silencing of ASS1 suggests the Potential Use of ADI-PEG 20 to Treat AML, Glioblastoma and Bladder Cancer

March 31, 2011

FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma

March 18, 2011

Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma

March 15, 2011

Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer

February 14, 2011

Polaris Group and the Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer


June 07, 2010

Phase II Clinical Trial Results of "ADI-PEG 20" Show Efficacy in Human Metastatic Melanoma Deficient in a Key Metabolic Enzyme, and in Lymphomas in Preclinical Studies

April 22, 2010

Multiple Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug "ADI-PEG 20"


April 17, 2009

Polaris Collaborator to Present Research into ADI-PEG 20's Mechanism of Action at AACR 2009

January 16, 2009

Advisory Panel Meeting Held in San Francisco: Plans for Phase 3 Trial of ADI-PEG 20 in HCC Patients Discussed

January 15, 2009

Polaris' ADI-PEG 20 Featured in Cancer Research Article: Novel Treatment for Prostate Cancer

January 14, 2009

Dr. Li-Tzong Chen to Present Results of Completed Asian Phase 2 Clinical Trial of ADI-PEG 20 Treatment for HCC at ASCO Gastrointestinal Cancers Symposium


December 31, 2008

Polaris Acquires TDW Pharmaceuticals, Inc.

December 15, 2008

USPTO Issues Notice of Allowance for Polaris' US Protein Kinase Inhibitors Patent

October 17, 2008

Press Conference Held in Taiwan to Announce the Results of a Phase 2 Trial of ADI-PEG 20 in Advanced HCC

October 15, 2008

Polaris' ADI-PEG 20 Featured in International Journal of Cancer Article: Novel Treatment for Pancreatic Cancer

May 28, 2008

Polaris Acquires Equity Stake in EnzymeRx


August 14, 2007

Ludwig Institute for Cancer Research Initiates Clinical Trial of Polaris' ADI-PEG 20 for the Treatment of Melanoma


March 30, 2006

Polaris Acquires Phoenix Pharmacologics, Inc. Intellectual Property